Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Cited by (1,010)

Items 101–200 of 1,010

1. Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
   Yuting Ma, Sandy Adjemian, Stephen R. Mattarollo, Takahiro Yamazaki, Laetitia Aymeric, Heng Yang, João Paulo Portela Catani, Dalil Hannani, Helene Duret, Kim Steegh et al. · 2013 · Immunity
2. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation
   Krysko, Dmitri V., Agostinis, Patrizia, Krysko, Olga, Garg, Abhishek D., Bachert, Claus, Lambrecht, Bart N., Vandenabeele, Peter · 2011 · Trends in Immunology
3. Apoptosis and necrosis: Detection, discrimination and phagocytosis
   Dmitri V. Krysko, Tom Vanden Berghe, Katharina G.M.A. D'Herde, Peter Vandenabeele · 2008 · Methods
4. Cancer-related inflammation: Common themes and therapeutic opportunities
   Frances R. Balkwill, Alberto Mantovani · 2011 · Seminars in Cancer Biology
5. Macrophages and cancer: from mechanisms to therapeutic implications
   Renato Ostuni, Franz Kratochvill, Peter J. Murray, Gioacchino Natoli · 2015 · Trends in Immunology
6. Radiotherapy combined with immunotherapy: the dawn of cancer treatment
   Zengfu Zhang, Xu Liu, Dawei Chen, Jinming Yu · 2022 · Signal Transduction and Targeted Therapy
7. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4
   Milena Schiraldi, Angela Raucci, Laura Martínez‐Muñoz, Elsa Livoti, Barbara Celona, Emilie Vénéreau, Tiziana Apuzzo, Francesco De Marchis, Mattia Pedotti, Angela Bachi et al. · 2012 · The Journal of Experimental Medicine
8. The secret ally: immunostimulation by anticancer drugs
   Lorenzo Galluzzi, Laura Senovilla, Laurence Zitvogel, Guido Kroemer · 2012 · Nature Reviews Drug Discovery
9. Immune parameters affecting the efficacy of chemotherapeutic regimens
   Laurence Zitvogel, Oliver Kepp, Guido Kroemer · 2011 · Nature Reviews Clinical Oncology
10. Dendritic cell subsets in cancer immunity and tumor antigen sensing
    Annalisa Del Prete, Valentina Salvi, Alessandra Soriani, Mattia Laffranchi, Francesca Sozio, Daniela Bosisio, Silvano Sozzani · 2023 · Cellular and Molecular Immunology
11. The Yin‐Yang of tumor‐associated macrophages in neoplastic progression and immune surveillance
    Paola Allavena, Antonio Sica, Cecília Garlanda, Alberto Mantovani · 2008 · Immunological Reviews
12. DNA Damage and Repair Biomarkers of Immunotherapy Response
    Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
13. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
    Karama Makni‐Maalej, Maysaloun Merhi, Varghese Philipose Inchakalody, Sarra Mestiri, Majid Ali Alam, Cristina Maccalli, Honar Cherif, Shahab Uddin M.S., Martin S. Steinhoff, Francesco Maria Marincola et al. · 2023 · Molecular Cancer
14. Immune Therapy for Cancer
    Michael Lawrence Dougan, Glenn Dranoff · 2008 · Annual Review of Immunology
15. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
    Tianyu Tang, Xing Huang, Gang Zhang, Zhengtao Hong, Xueli Bai, Tingbo Liang · 2021 · Signal Transduction and Targeted Therapy
16. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
    Roberto Salgado, Carsten Denkert, Christine Campbell, Peter Stephen Savas, Paolo Giovanni Nuciforo, Claudia Monica Aura, Evandro de Azambuja, Holger Eidtmann, Catherine Elizabeth Ellis, Jose M Baselga et al. · 2015 · JAMA Oncology
17. Cancer related inflammation: the macrophage connection
    Sica, Antonio, Allavena, Paola, Mantovani, Alberto · 2008 · Cancer Letters
18. High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity
    Bianchi, Marco E., Manfredi, Angelo A. · 2007 · Immunological Reviews
19. Therapeutic Cancer Vaccines
    Chunqing Guo, Masoud H. Manjili, John R. Subjeck, Devanand Sarkar, Paul B. Fisher, Xiang‐Yang Wang · 2013 · Advances in cancer research
20. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future
    Niloy Ranjan Datta, Silvia Gómez Ordóñez, Udo S. Gaipl, Margarethus Marius Paulides, Johannes Crezee, Johanna Gellermann, Dietmar Marder, Emsad Puric, Stephan B. Bodis · 2015 · Cancer Treatment Reviews
21. Cancer Immunotherapy Comes of Age
    Suzanne Louise Topalian, George J. Weiner, Drew M. Pardoll · 2011 · Journal of Clinical Oncology
22. Intestinal Bacteria and the Regulation of Immune Cell Homeostasis
    David A. Hill, David Artis · 2010 · Annual Review of Immunology
23. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
    Park, SaeGwang, Jiang, Zhujun, Mortenson, Eric D., Deng, Liufu, Radkevich-Brown, Olga, Yang, Xuanming, Sattar, Husain, Wang, Yang, Brown, Nicholas K., Greene, Mark et al. · 2010 · Cancer Cell
24. Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
    Zhenyu Zhong, Elsa Sánchez‐López, Michael Karin · 2016 · Cell
25. The hallmarks of cancer immune evasion
    Claudia Galassi, Timothy An-thy Chan, Ilio Vitale, Lorenzo Galluzzi · 2024 · Cancer Cell
26. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
    Lionel Apétoh, François Ghiringhelli, Antoine Tesnière, Alfredo Criollo, Carla Ortiz, Rosette Lidereau, C. Mariette, Nathalie Chaput, Jean Paul Mira, Suzette Delaloge et al. · 2007 · Immunological Reviews
27. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
    Kobe Reynders, Tim Illidge, Shankar Siva, Joe Yujiao Chang, Dirk De Ruysscher · 2015 · Cancer Treatment Reviews
28. Extracellular adenosine triphosphate and adenosine in cancer
    John Stagg, Mark John Smyth · 2010 · Oncogene
29. Innate Immune Recognition of Cancer
    Seng‐Ryong Woo, Leticia P. Corrales, Thomas F. Gajewski · 2015 · Annual Review of Immunology
30. The anticancer immune response: indispensable for therapeutic success?
    Laurence Zitvogel, Lionel Apétoh, François Ghiringhelli, Fabrice André, Antoine Tesnière, Guido Kroemer · 2008 · Journal of Clinical Investigation
31. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
    Leisha A. Emens, Paolo A. Ascierto, Phillip Kevin Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco Maria Marincola · 2017 · European Journal of Cancer
32. Advances in cancer immunotherapy 2019 – latest trends
    Stephan Krüger, Matthias Ilmer, Sebastian Kobold, Bruno Loureiro Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard Willibald Renz, Jan Goesta D’Haese, Hans Schlößer et al. · 2019 · Journal of Experimental & Clinical Cancer Research
33. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    Susan F. Slovin, Celestia S. Higano, Omid Hamid, Sheela Tejwani, Andrea Lynne Harzstark, Joshi J. Alumkal, Howard I. Scher, Kevin M. Chin, Paul Gagnier, M. Brent McHenry et al. · 2013 · Annals of Oncology
34. Cell death assays for drug discovery
    Oliver Kepp, Lorenzo Galluzzi, Marta M. Lipinski, Junying Yuan, Guido Kroemer · 2011 · Nature Reviews Drug Discovery
35. The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved?
    J. Martin Brown, David J. Carlson, David J. Brenner · 2014 · International Journal of Radiation Oncology*Biology*Physics
36. Endogenous toll‐like receptor ligands and their biological significance
    Li Yu, Liantang Wang, Shangwu Chen · 2010 · Journal of Cellular and Molecular Medicine
37. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
    Iuliia Efimova, Elena Catanzaro, Louis Van der Meeren, Victoria D. Turubanova, Hamida Hammad, Tatiana A. Mishchenko, Maria V. Vedunova, Carmela Fimognari, Claus Bachert, Frauke Coppieters et al. · 2020 · Journal for ImmunoTherapy of Cancer
38. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
39. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
    Kyohei Nakamura, Mark John Smyth · 2019 · Cellular and Molecular Immunology
40. Endogenous ligands of TLR2 and TLR4: agonists or assistants?
    Clett Erridge · 2010 · Journal of Leukocyte Biology
41. High-mobility group box 1 and cancer
    Daolin Tang, Rui Kang, Herbert J. Zeh, Michael T. Lotze · 2010 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
42. Radiotherapy combination opportunities leveraging immunity for the next oncology practice
    Fernanda Gabriela Herrera, Jean Bourhis, George Coukos · 2016 · CA A Cancer Journal for Clinicians
43. Alarmins: awaiting a clinical response
    James K-K. Chan, Johannes Roth, Joost J. Oppenheim, Kevin J. Tracey, Thomas Vogl, Marc Feldmann, Nicole J. Horwood, Jagdeep Nanchahal · 2012 · Journal of Clinical Investigation
44. Cancer Immunotherapy by Dendritic Cells
    Cornelis J.M. Melief · 2008 · Immunity
45. Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade
    Fangyuan Zhou, Bing Feng, Haijun Yu, Dangge Wang, Tingting Wang, Yuting Ma, Siling Wang, Yaping Li · 2019 · Advanced Materials
46. Interleukin 12: still a promising candidate for tumor immunotherapy?
    Lasek, Witold, Zagożdżon, Radosław, Jakobisiak, Marek · 2014 · Cancer Immunology Immunotherapy
47. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
    Maria Esperanza Rodriguez-Ruiz, Claire Vanpouille‐Box, Ignacio Melero, Silvia Chiara Formenti, Sandra Demaria · 2018 · Trends in Immunology
48. Myeloid-derived suppressor cells in cancer and cancer therapy
    Samantha Lasser, Feyza Gül Özbay Kurt, Ihor Arkhypov, Jochen Sven Utikal, Viktor Umansky · 2024 · Nature Reviews Clinical Oncology
49. Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
    Abhishek Dinkarnath Garg, Dominika Nowis, Jakub Gołąb, Peter Vandenabeele, Dmitri V. Krysko, Patrizia Agostinis · 2009 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
50. Recent Developments in Radiotherapy
    Deborah E. Citrin · 2017 · New England Journal of Medicine
51. Intratumoural administration and tumour tissue targeting of cancer immunotherapies
    Ignacio Melero, Eduardo Castañón Álvarez, Maite Álvarez, Stéphane Champiat, Aurélien Marabelle · 2021 · Nature Reviews Clinical Oncology
52. Decoding Cell Death Signals in Inflammation and Immunity
    Zitvogel, Laurence, Kepp, Oliver, Kroemer, Guido · 2010 · Cell
53. Molecular characteristics of immunogenic cancer cell death
    Antoine Tesnière, Theocharis Panaretakis, Oliver Kepp, Lionel Apétoh, François Ghiringhelli, Laurence Zitvogel, Guido Kroemer · 2007 · Cell Death and Differentiation
54. HMGB1 in Cancer: Good, Bad, or Both?
    Rui Kang, Qiuhong Zhang, Herbert J. Zeh, Michael T. Lotze, Daolin Tang · 2013 · Clinical Cancer Research
55. Microbiome and Anticancer Immunosurveillance
    Zitvogel, Laurence, Ayyoub, Maha, Routy, Bertrand, Kroemer, Guido · 2016 · Cell
56. Damage-associated molecular patterns in cancer: a double-edged sword
    Céline Hernandez, Peter Huebener, Robert F. Schwabe · 2016 · Oncogene
57. Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
    Marcin Kortylewski, Hong Xin, Maciej Kujawski, Heehyoung Lee, Yong Liu, Timothy Harris, Charles G. Drake, Drew M. Pardoll, Hua Yu · 2009 · Cancer Cell
58. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
    Alexander Filatenkov, Jeanette B Baker, Antonia M. S. Müller, Justin A. Kenkel, G‐One Ahn, Suparna Dutt, Nigel Zhang, Holbrook E K Kohrt, Kent P. Jensen, Sussan Dejbakhsh‐Jones et al. · 2015 · Clinical Cancer Research
59. Integrated Magneto–Electrochemical Sensor for Exosome Analysis
    Sangmoo Jeong, Jongmin Park, Divya Pathania, Cesar Martin Castro, Ralph Weissleder, Hakho Lee · 2016 · ACS Nano
60. Strategies for optimizing the response of cancer and normal tissues to radiation
    Everett James Moding, Michael B. Kastan, David G. Kirsch · 2013 · Nature Reviews Drug Discovery
61. Radiotherapy and Immunogenic Cell Death
    Encouse B. Golden, Lionel Apétoh · 2014 · Seminars in Radiation Oncology
62. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells
    Tang, D, Kang, R, Cheh, C-W, Livesey, K M, Liang, X, Schapiro, N E, Benschop, R, Sparvero, L J, Amoscato, A A, Tracey, K J et al. · 2010 · Oncogene
63. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
    Achim Rody, Uwe Holtrich, L. Pusztai, Cornelia Liedtke, R. Gaetje, Eugen Ruckhaeberle, Christine Solbach, Lars Hanker, Andre Ahr, Dirk Metzler et al. · 2009 · Breast Cancer Research
64. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
    Rupal Ramakrishnan, Deepak Assudani, Srinivas Nagaraj, Terri B. Hunter, Hyun-Il Cho, Scott Joseph Antonia, Soner Altiok, Esteban Celis, Dmitry I. Gabrilovich · 2010 · Journal of Clinical Investigation
65. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
    Makoto Nishio, Fabrice Barlési, Howard West, Simon Ball, Rodolfo Eduardo Bordoni, Manuel Cobo, Pascale Dubray‐Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi et al. · 2020 · Journal of Thoracic Oncology
66. CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens
    Kenichi Asano, Ami Nabeyama, Yasunobu Miyake, Chun‐Hong Qiu, Ai Kurita, Michio Tomura, Osami Kanagawa, Shin‐ichiro Fujii, Masato Tanaka · 2010 · Immunity
67. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
    Maria Vittoria Dieci, Carmen Criscitiello, Aïcha Goubar, Giuseppe Viale, PierFranco Conte, Valentina Guarneri, Guido Ficarra, Marie Christine Mathieu, Suzette Delaloge, Giuseppe Curigliano et al. · 2014 · Annals of Oncology
68. Inflammation and oncogenesis: a vicious connection
    Sergei I. Grivennikov, Michael Karin · 2009 · Current Opinion in Genetics & Development
69. HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
    Bertheloot, Damien, Latz, Eicke · 2017 · Cellular & Molecular Immunology
70. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
    Vacchelli, Erika, Ma, Yuting, Baracco, Elisa E., Sistigu, Antonella, Enot, David P., Pietrocola, Federico, Yang, Heng, Adjemian, Sandy, Chaba, Kariman, Semeraro, Michaela et al. · 2015 · Science
71. Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
    Stanleyson V. Hato, Andrea Khong, I. Jolanda M. de Vries, Willem Joost Lesterhuis · 2014 · Clinical Cancer Research
72. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment
    Bing Feng, Fangyuan Zhou, Bo Hou, Dangge Wang, Tingting Wang, Yuanlei Fu, Yuting Ma, Haijun Yu, Yaping Li · 2018 · Advanced Materials
73. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma
    Karīna Siliņa, Alex Soltermann, Farkhondeh Movahedian Attar, Ruben Casanova, Zina M. Uckeley, Helen Thut, Muriel Wandres, Sergejs Isajevs, Phil Fang Cheng, Alessandra Curioni Fontecedro et al. · 2017 · Cancer Research
74. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
    Wenxi Zhou, Yu Zhou, Xinli Chen, Tingting Ning, Hongyi Chen, Qin Guo, Yiwen Zhang, Peixin Liu, Yujie Zhang, Chao Li et al. · 2020 · Biomaterials
75. Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity
    Tania Løve Aaes, Agnieszka Kaczmarek, Tinneke Delvaeye, Bram De Craene, Stefaan De Koker, Liesbeth Heyndrickx, Iris Delrue, Joachim Taminau, Bartosz Wiernicki, Philippe De Groote et al. · 2016 · Cell Reports
76. Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
    Anurag Kumar Gupta, Hans Christian Probst, Van Vuong, Alexandro Landshammer, Sabine Muth, Hideo Yagita∥, Reto Albert Schwendener, Martin N. Pruschy, Alexander K. Knuth, Maries F. van den Broek · 2012 · The Journal of Immunology
77. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    Naiyer A. Rizvi, Matthew David Hellmann, Julie Renee Brahmer, Rosalyn Anne Juergens, Hossein Borghaei, Scott N. Gettinger, Laura Q.M. Chow, David E. Gerber, Scott Andrew Laurie, Jonathan Wade Goldman et al. · 2016 · Journal of Clinical Oncology
78. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
    Abhishek Dinkarnath Garg, Patrizia Agostinis · 2017 · Immunological Reviews
79. Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
    Turid Hellevik, Iñigo Martínez-Zubiaurre · 2014 · Frontiers in Oncology
80. Abscopal effects of radiation therapy: A clinical review for the radiobiologist
    Shankar Siva, Michael Patrick MacManus, Roger F. Martin, Olga A. Martin · 2013 · Cancer Letters
81. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
    Jianqin Lu, Xiangsheng Liu, Yu‐Pei Liao, Felix B. Salazar, Bingbing Sun, Wen Jiang, Chong Hyun Chang, Jinhong Jiang, Xiang Wang, Anna M. Wu et al. · 2017 · Nature Communications
82. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
    Linda Hammerich, Thomas Urban Marron, Ranjan Upadhyay, Judit Svensson‐Arvelund, Maxime Dhainaut, Shafinaz Hussein, Yougen Zhan, Dana Ostrowski, Michael Jay Yellin, Henry C. Marsh et al. · 2019 · Nature Medicine
83. Identification and manipulation of tumor associated macrophages in human cancers
    Moniek Heusinkveld, Sjoerd H. van der Burg · 2011 · Journal of Translational Medicine
84. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands
    Xiaoxia Z. West, Nikolay L. Malinin, Alona A. Merkulova, Mira Tischenko, Bethany A. Kerr, Ernest C. Borden, Eugene A. Podrez, Robert G. Salomon, Tatiana V. Byzova · 2010 · Nature
85. Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
    Menger, Laurie, Vacchelli, Erika, Adjemian, Sandy, Martins, Isabelle, Ma, Yuting, Shen, Shensi, Yamazaki, Takahiro, Sukkurwala, Abdul Qader, Michaud, Mickaël, Mignot, Grégoire et al. · 2012 · Science Translational Medicine
86. Cross-priming in health and disease
    Christian Kurts, Bruce W.S. Robinson, Percy Alexander Knolle · 2010 · Nature reviews. Immunology
87. Cancer immunotherapy – revisited
    Willem Joost Lesterhuis, John B.A.G. Haanen, Cornelis J.A. Punt · 2011 · Nature Reviews Drug Discovery
88. Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor
    Dietmar M. W. Zaiss, Jorg van Loosdregt, Andrea Gorlani, Cornelis P. J. Bekker, Andrea Gröne, Maria Chiara Sibilia, Paul M.P. van Bergen en Henegouwen, Rob C. Roovers, Paul James Coffer, Alice J.A.M. Sijts · 2013 · Immunity
89. Tumor Microenvironment and Differential Responses to Therapy
    Hirata, Eishu, Sahai, Erik · 2017 · Cold Spring Harbor Perspectives in Medicine
90. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
    Sofia R. Gameiro, Momodou L. Jammeh, Max Miller Wattenberg, Kwong Yok Tsang, Soldano Ferrone, James W. Hodge · 2013 · Oncotarget
91. Secondary necrosis: The natural outcome of the complete apoptotic program
    Manuel T. Silva · 2010 · FEBS Letters
92. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner
    Wanderley, Carlos W., Colón, David F., Luiz, João Paulo M., Oliveira, Francisco F., Viacava, Paula R., Leite, Caio A., Pereira, Janaina A., Silva, Camila M., Silva, Cassia R., Silva, Rangel L. et al. · 2018 · Cancer Research
93. HMGB1 loves company
    Marco Emilio Bianchi · 2009 · Journal of Leukocyte Biology
94. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
    Abhishek Dinkarnath Garg, Lorenzo Galluzzi, Lionel Apétoh, Thaïs Baert, Raymond B. Birge, José Manuel Bravo‐San Pedro, Karine Breckpot, David Brough, Ricardo A. Chaurio, Mara Cirone et al. · 2015 · Frontiers in Immunology
95. Calreticulin and cancer
    Jitka Palich Fucikova, Radek Špíšek, Guido Kroemer, Lorenzo Galluzzi · 2020 · Cell Research
96. Alarmins and immunity
    De Yang, Zhen Han, Joost J. Oppenheim · 2017 · Immunological Reviews
97. Innate immune signaling and regulation in cancer immunotherapy
    Corrales, Leticia, Matson, Vyara, Flood, Blake, Spranger, Stefani, Gajewski, Thomas F · 2017 · Cell Research
98. Autophagy and cancer therapy
    Paola Maycotte, Andrew M. Thorburn · 2011 · Cancer Biology & Therapy
99. Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
    Jitka Palich Fucikova, Petra Králíková, Anna Fialová, Tomáš Brtnický, Lukáš Rob, Jiřina Bartůňková, Radek Špíšek · 2011 · Cancer Research
100. Combinatorial Strategies for the Induction of Immunogenic Cell Death
     Lucillia Bezu, Lígia Catarina Gomes-da-Silva, Heleen Dewitte, Karine Breckpot, Jitka Palich Fucikova, Radek Špíšek, Lorenzo Galluzzi, Oliver Kepp, Guido Kroemer · 2015 · Frontiers in Immunology